A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
Clinical trial NCT03591653 · COMPLETED
Trial details
- NCT number
- NCT03591653
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-29
- Primary completion
- 2019-10-30
- Enrollment
- 291
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.